Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

123.62 -1.05 (-0.84%)
Official Closing Price Updated: 4:10 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
49 50 Next >
What the Options Market Tells Us About Abbott Laboratories
 
Via Benzinga
What's Going On With Abbott Laboratories Stock On Friday?
An Illinois jury orders Reckitt Benckiser's Mead Johnson to pay $60 million after a premature infant's tragic death linked to Enfamil baby formula. Mead Johnson found negligent for not warning about... 
Via Benzinga
Topics Lawsuit
Why Abbott's Formula-Related Sell-Off Could Be A Buying Opportunity, Says Analyst
Fellow infant formula maker Reckitt Benckiser was ordered to pay $60 million to a mother whose baby died after eating Enfamil. 
Via Investor's Business Daily
Topics Death
SCHD ETF Spotlight: The Top 6 Stocks Inside This Dividend Monster
With over 100 dividend growth stocks in its portfolio, the SCHD ETF has proved to be a formidable income-generating vehicle for investors. 
Via InvestorPlace
Topics ETFs
Medtronic is a Dividend Aristocrat That Keeps Gaining
A strong earnings report backed by raised guidance adds to the allure of Medtronic stock, which is already a Dividend Aristocrat in the healthcare sector 
Via MarketBeat
$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Is Abbott Laboratories a Top Dividend Growth Stock to Buy Now?
Abbott Laboratories has been growing its dividend at a blistering pace. Is its stock a buy? 
Via The Motley Fool
3 Dividend Kings of Healthcare Stocks to Buy Hand Over Fist in March
These are some of the best-performing stocks in what's arguably society's most important industry. 
Via The Motley Fool
Are These 5 Undervalued Stocks Ready to Break Out?
Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices. 
Via MarketBeat
FDA Approval For DexCom's Stelo Opens Continuous Glucose Monitoring To Masses, Analyst Expects Competitive Pricing Against Abbott's
FDA greenlights DexCom's Stelo, the first OTC continuous glucose monitor for non-insulin-dependent diabetics. Competitive pricing, potential HSA benefits, and market expansion make it a significant... 
Via Benzinga
3 Dividend Aristocrats With the Largest 10-Year Dividend Growth Rates
These three dividend stocks have proved themselves to be among the best Dividend Aristocrats to buy for high-growth returns. 
Via InvestorPlace
Exploring ABBOTT LABORATORIES (NYSE:ABT)s quality characteristics.
Why the quality investor may take a look at ABBOTT LABORATORIES (NYSE:ABT). 
Via Chartmill
$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Could Abbott Laboratories Stock Help You Become a Millionaire?
Abbott's earnings have soared over the past decade. 
Via The Motley Fool
Why Dexcom — And The Obesity Market — Could Benefit From This New FDA Win
The FDA granted Dexcom's Stelo a broad clearance, meaning people without diabetes can use it. 
Via Investor's Business Daily
Ozempic Won't Sink This Medical Device Stock's Prospects -- Quite the Opposite
There is a world of opportunities ahead for this healthcare giant. 
Via The Motley Fool
Nearing Retirement? These Stocks Are as Cautious as They Come
Healthcare blue chips can provide retirees the consistency they need while growing their nest eggs further. 
Via The Motley Fool
3 Magnificent Dividend Growth Stocks to Buy Now and Hold for at Least a Decade
These stocks don't offer the highest yields, but their payouts are growing fast. 
Via The Motley Fool
3 Blue-Chip Stocks to Buy to Bolster Your Portfolio
Delve into three undervalued blue-chip stocks to buy driving growth in consumer staples, pharmaceuticals, and healthcare. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Abbott Laboratories (NYSE: ABT) Records 52-Week High Friday Morning
Via Investor Brand Network
Abbott Laboratories Options Trading: A Deep Dive into Market Sentiment
 
Via Benzinga
Looking for Growth? 7 Hot Trends That Have Been Flying Under Investors’ Radar.
Discover 7 under-the-radar stock trends set to make waves in the stock market. Find out why savvy investors are tuning in. 
Via InvestorPlace
Recession-Proof Riches: 7 Stocks to Buy for Bulletproof Portfolio Growth
Explore recession-proof stocks thriving in Energy, Health Care, Industrials, and more, offering stability and growth amid economic turmoil. 
Via InvestorPlace
Abbott Laboratories Stock Gets A Healthy Technical Rating Upgrade
In a welcome move, Abbott Laboratories stock saw its Relative Strength Rating improve from 67 to 73 on Wednesday. 
Via Investor's Business Daily
Peering Into Abbott Laboratories's Recent Short Interest
 
Via Benzinga
3 Cash Cows to Boost Your Confidence During the February Chill
The market can be a tricky place. Bet on these cash cow stocks to help restore confidence and extract steady returns. 
Via InvestorPlace
The Smartest Dividend Stocks to Buy With $400 Right Now
These stocks reward you during any market environment. 
Via The Motley Fool
Cardiology's Quantum Leap: FDA's Advisory Panel Gives Thumbs Up To Abbott's Minimally Invasive Heart Valve Repair Device
FDA panel confirms support (13-1) for Abbott Laboratories' TriClip TEER system in treating tricuspid regurgitation. Approval decision expected from FDA in 2024. 
Via Benzinga
FDA Advisors Set To Discuss Abbott's TriClip For Heart Valve Disorder As Questions On Pivotal Trial Loom
FDA to review Abbott's TriClip G4 System for severe tricuspid regurgitation. Circulatory System Devices Panel meeting and insights from the briefing document. 
Via Benzinga
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
49 50 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.